Gastroesophageal reflux incidence and respiratory dysfunction during sleep in infants: treatment with cisapride. 1989

Y Vandenplas, and M Deneyer, and M Verlinden, and T Aerts, and L Sacre
Academic Children's Hospital, Free University of Brussels, Belgium.

We studied the effects of positional treatment and cisapride (a new prokinetic agent) on the incidence and duration of gastroesophageal reflux in 22 infants (4-26 weeks old) in asleep, awake, fasted, and postcibal periods. In addition to gastroesophageal reflux (assessed by 24-h continuous esophageal pH monitoring), all infants presented with a disrupted irregular sleep pattern ("respiratory dysfunction") (assessed by a simultaneously performed cardiopneumogram). Reflux was particularly prominent during the sleep and fasted periods. Investigations (cardiopneumogram and esophageal pH monitoring) in the study population were repeated under treatment conditions (cisapride) after 13-16 days. All pH monitoring data with regard to the total investigation time decreased significantly (p less than 0.001). The treatment-related differences were largest in the asleep and fasted periods, but treatment data were not completely within normal ranges (established in age-matched asymptomatic infants), as they were for the awake periods. Associated symptoms of gastroesophageal reflux (belching, cough, nocturnal wheezing, irritability, and restlessness at night) were evaluated before and during treatment by history. A combination of positional treatment and cisapride seemed effective (objectivated by pH monitoring data and clinical improvement); cisapride did not cause adverse reactions. The disrupted sleep pattern improved significantly or disappeared (p less than 0.001) in all infants. These data suggest that in a number of young infants, gastroesophageal reflux may be associated with a disturbed, irregular sleep of poor quality, which is characterized by a typical breathing pattern (multiple, irregularly repeated, short apneas).

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D010880 Piperidines A family of hexahydropyridines.
D011187 Posture The position or physical attitude of the body. Postures
D005764 Gastroesophageal Reflux Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER. Esophageal Reflux,Gastro-Esophageal Reflux Disease,GERD,Gastric Acid Reflux,Gastric Acid Reflux Disease,Gastro-Esophageal Reflux,Gastro-oesophageal Reflux,Gastroesophageal Reflux Disease,Reflux, Gastroesophageal,Acid Reflux, Gastric,Gastro Esophageal Reflux,Gastro Esophageal Reflux Disease,Gastro oesophageal Reflux,Gastro-Esophageal Reflux Diseases,Reflux Disease, Gastro-Esophageal,Reflux, Gastric Acid,Reflux, Gastro-Esophageal,Reflux, Gastro-oesophageal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012891 Sleep Apnea Syndromes Disorders characterized by multiple cessations of respirations during sleep that induce partial arousals and interfere with the maintenance of sleep. Sleep apnea syndromes are divided into central (see SLEEP APNEA, CENTRAL), obstructive (see SLEEP APNEA, OBSTRUCTIVE), and mixed central-obstructive types. Apnea, Sleep,Hypersomnia with Periodic Respiration,Sleep-Disordered Breathing,Mixed Central and Obstructive Sleep Apnea,Sleep Apnea, Mixed,Sleep Apnea, Mixed Central and Obstructive,Sleep Hypopnea,Apnea Syndrome, Sleep,Apnea Syndromes, Sleep,Apneas, Sleep,Breathing, Sleep-Disordered,Hypopnea, Sleep,Hypopneas, Sleep,Mixed Sleep Apnea,Mixed Sleep Apneas,Sleep Apnea,Sleep Apnea Syndrome,Sleep Apneas,Sleep Apneas, Mixed,Sleep Disordered Breathing,Sleep Hypopneas
D020117 Cisapride A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed) Propulsid,R-51619,R 51619,R51619

Related Publications

Y Vandenplas, and M Deneyer, and M Verlinden, and T Aerts, and L Sacre
April 2001, Pediatrics,
Y Vandenplas, and M Deneyer, and M Verlinden, and T Aerts, and L Sacre
July 1989, Journal of pediatric gastroenterology and nutrition,
Y Vandenplas, and M Deneyer, and M Verlinden, and T Aerts, and L Sacre
May 1992, The American journal of gastroenterology,
Y Vandenplas, and M Deneyer, and M Verlinden, and T Aerts, and L Sacre
May 2023, Children (Basel, Switzerland),
Y Vandenplas, and M Deneyer, and M Verlinden, and T Aerts, and L Sacre
November 1997, Journal of pediatric gastroenterology and nutrition,
Y Vandenplas, and M Deneyer, and M Verlinden, and T Aerts, and L Sacre
February 2000, Pediatrics,
Y Vandenplas, and M Deneyer, and M Verlinden, and T Aerts, and L Sacre
January 1995, Scandinavian journal of gastroenterology. Supplement,
Y Vandenplas, and M Deneyer, and M Verlinden, and T Aerts, and L Sacre
September 1992, Scandinavian journal of gastroenterology,
Y Vandenplas, and M Deneyer, and M Verlinden, and T Aerts, and L Sacre
January 1988, Clinical therapeutics,
Y Vandenplas, and M Deneyer, and M Verlinden, and T Aerts, and L Sacre
April 2013, Journal of pediatric gastroenterology and nutrition,
Copied contents to your clipboard!